1		OVINGTON & BURLING LLP				
2	* /	fichael X. Imbroscio ( <i>pro hac vice</i> ) nimbroscio@cov.com)				
3	Rakesh Kilaru (pro hac vice) O	ne City Center				
		50 10th St. NW Vashington, DC 20001				
4		el: 202-662-6000				
5	Washington, DC 20036					
6	Tel: 202-847-4030 Fax: 202-847-4005					
7	HOLLINGSWORTH LLP					
8	Eric G. Lasker (pro hac vice)					
9	(elasker@hollingsworthllp.com) 1350 I St. NW					
	Washington, DC 20005					
10	Tel: 202-898-5843					
11	Fax: 202-682-1639					
12	Attorneys for Defendant MONSANTO COMPANY					
13						
14	UNITED STATES DISTRICT COURT					
15	NORTHERN DISTRICT OF CALIFORNIA					
16						
	IN RE: ROUNDUP PRODUCTS LIABILITY LITIGATION	MDL No. 2741				
17	LIABILITY LITIGATION	Case No.: 3:16-md-02741-VC				
18						
19	Cervantes v. Monsanto Co., 3:19-cv-03015-VC	DEFENDANT MONSANTO				
20	Karman v. Monsanto Co., 3:19-ev-01183-VC	COMPANY'S NOTICE OF MOTION AND MOTION TO				
	Pecorelli v. Monsanto Co., 3:16-cv-06936-VC	EXCLUDE TESTIMONY OF				
21	Peterson v. Monsanto Co., 3:18-cv-07271-VC	PLAINTIFFS' EXPERTS BARRY BOYD, LAUREN PINTER-				
22	Rehak v. Monsanto Co., 3:19-cv-01719-VC	BROWN, AND RON SCHIFF ON RULE 702 GROUNDS				
23	Schafer v. Monsanto Co., 3:19-cv-02169					
24	Seidl v. Monsanto Co., 3:17-cv-00519-VC	Hearing date: May 28, 2021 Time:				
25						
26						
2.7						



TO THE COURT, ALL PARTIES, AND THEIR	RATIORNEYS OF RECORD:		
PLEASE TAKE NOTICE THAT beginning on May 28, 2021, in Courtroom 4 of the United States			
District Court, Northern District of California, loca	District Court, Northern District of California, located at 450 Golden Gate Avenue, San Francisco,		
CA 94102, or as ordered by the Court, Defendant N	CA 94102, or as ordered by the Court, Defendant Monsanto Company ("Monsanto") will present its		
Motion to Exclude Testimony of Barry Boyd, Laure	Motion to Exclude Testimony of Barry Boyd, Lauren Pinter-Brown, and Ron Schiff. Monsanto seeks		
an order excluding opinion of this witness under Fed	an order excluding opinion of this witness under Federal Rule of Evidence 702 and Daubert v. Merrell		
7 Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).	Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).		
3			
DATED: March 19, 2021			
Respe	etfully submitted,		
/s/ Mic	chael X. Imbroscio		
	el X. Imbroscio ( <i>pro hac vice</i> ) proscio@cov.com)		
Coving	gton & Burling LLP		
	ity Center 0th St. NW		
· II	ngton, DC 20001 02-62-6000		
5	, <b>-</b>		
7			
3			
1			
$2 \parallel$			
3			
1			
5			
5			
7			
2 3 4 5 6 7 3 9 9 1 1 2 3 4 5 6 7 3 4 5 6 7 6 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8	PLEASE TAKE NOTICE THAT beginning on M. District Court, Northern District of California, local CA 94102, or as ordered by the Court, Defendant M. Motion to Exclude Testimony of Barry Boyd, Laure an order excluding opinion of this witness under Fed. Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).  DATED: March 19, 2021  Respectively.  Michaland (mimb. Coving One C. 850 10 Washi		



## **TABLE OF CONTENTS**

2						
3	INTR	INTRODUCTION				
4	BACI	BACKGROUND				
5	I.	Wave Who	e Two Plaintiffs Have Disclosed a Handful of Specific Causation Experts for m the Court Has Not Previously Ruled	2		
6	II.	The V	Wave Two Plaintiffs All Had Risk Factors Associated with NHL	3		
7 8	III.	Plain Speci	tiffs' Experts All Purport to Use a Differential "Etiology" in Forming Their ific Causation Opinions.	6		
9	LEGA	AL STA	ANDARD	7		
10	ARG	UMEN'	T	8		
11	I.	Dr. S Meth	chiff's Testimony Reveals That the Experts' "Differential Etiology" odology Is Results Driven and Made for Litigation	8		
12 13	II.	Plain	tiffs' Experts Failed to Properly Assess Potential Alternative Causes of tiffs' NHL.			
14		A.	Dr. Schiff Admits He Cannot Rule Out or Weigh Risk Factors, and Always Concludes Roundup was a Substantial Cause.	10		
15 16		В.	Dr. Pinter-Brown Likewise Automatically Includes Roundup as a Substantial Cause and Does Not Weigh or Eliminate Other Risk Factors	15		
17		C.	Dr. Boyd Also Does Not Meaningfully Consider Alternative Causes, and His Testimony Regarding His Methodology Conflicts with Dr. Schiff's	17		
18 19	III.	Plain NHL	tiffs' Experts Have Not Reliably Ruled Out Unknown Causes of Plaintiffs and Instead Always Point to Roundup	18		
20	IV.	Mons a Cau	santo Preserves Its Arguments That Plaintiffs' Experts Ruled in Roundup as use of Each Plaintiff's NHL Based on Inadequate and Flawed Studies	19		
21	CON	CONCLUSION2				
22						
23						
24						
25						
26						
27						
28			<u>.</u>			



# TABLE OF AUTHORITIES

2	Page(s)
3	<u>Cases</u>
4 5	In re Aredia & Zometa Prod. Liab. Litig., 483 F. App'x 182 (6th Cir. 2012)
6	Claar v. Burlington N. R.R. Co., 29 F.3d 499 (9th Cir. 1994)
7 8	Clausen v. M/V New Carissa, 339 F.3d 1049 (9th Cir. 2003)
9 10	Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 589 (1993)
11	Hayes v. Tractor Supply Co., 170 N.C. App. 405, 612 S.E.2d 399 (2005)
12 13	In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices & Prod. Liab. Litig., 892 F.3d 624 (4th Cir. 2018)
14 15	In re Mirena Ius Levonorgestrel-Related Products Liability Litigation (No. II), 341 F.Supp.3d 213, 241 (S.D.N.Y., 2018)
16	Poust v. Huntleigh Healthcare, 998 F. Supp. 478 (D.N.J. 1998)
17 18	In re Roundup Prods. Liab. Litig., 358 F. Supp. 3d 956, 957 (N.D. Cal. 2019)
19 20	Solis v. BASF Corp., 979 N.E.2d 419, 365 Ill.Dec. 815 (Ill. App. 1 Dist., 2012)
21	Wehmeier v. UNR Indus., Inc., 213 Ill. App. 3d 6, 572 N.E.2d 320 (1991)
22 23	Westberry v. Gislaved Gummi AB, 178 F.3d 257 (4th Cir. 1999)
24	<i>Yates v. Ford Motor Co.</i> , No. 5:12-CV-752-FL, 2015 WL 3463559 (E.D.N.C. May 30, 2015)
<ul><li>25</li><li>26</li></ul>	Other Authorities
20 27	Federal Rule of Evidence 702
28	



1

#### INTRODUCTION

The Wave 2 Plaintiffs have designated an array of new specific causation experts that do not meet the standards of Rule 702 this Court imposed in Pre-Trial Order 85 ("PTO 85"). While purporting to rely on the same differential etiology/diagnosis methodology the Court previously permitted, these experts in fact fall woefully short of the first round of experts, which this Court bluntly described to have "barely inched over the line" in opining that Roundup®-branded products ("Roundup") specifically caused the plaintiffs' non-Hodgkin's lymphoma (NHL). In striking manner, each of these new experts is nakedly outcome-driven. To be sure, they continue to "rule in" Roundup based on the same flawed studies the general causation experts rely on without accounting for the Plaintiffs' specific NHL sub-types. But even setting that deficiency aside, they do their real methodological violence in their consideration of other potential risk factors. In their unwavering adherence to their conclusion that Roundup is always to blame, they offer no coherent, defensible principle undergirding their specific causation opinions, ultimately acknowledging that they cannot rule out many significant risk factors and instead simply professing no obligation to do so.

The mere invocation of the phrase "differential etiology" or "differential diagnosis" cannot sanitize what is otherwise an outcome-driven conclusion devoid of any reliable scientific basis. These experts repeatedly failed to reliably account for *known* risk factors for NHL that other plaintiffs' experts admit are well-accepted risk factors, and they at the same time casually ignore the potential that unknown factors, which account for most NHL cases, might explain the plaintiff's NHL.

And unlike the experts the Court previously addressed, these experts fully admit they have no reliable scientific method to weigh causes against one another—the very subject on which their testimony will purportedly assist a jury under Rule 702. The bottom line for these witnesses is that Roundup will always be the cause of every plaintiff's NHL as long as the plaintiff was exposed to some amount of Roundup at some point in their life—regardless of the plaintiff's individual medical history and risk factors, regardless of the fact that the cause of NHL cannot be determined in the vast majority of cases, and regardless of when or how much a plaintiff allegedly used Roundup. That is not science—that is courtroom advocacy in a lab coat. This Court has previously described the "daunting challenge" of establishing specific causation in these cases. These new experts do not meet



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

